BioCentury
ARTICLE | Product Development

AACR Quick Takes: Guardant, Gracell, iTeos, Zentalis, ImCheck, PureTech   

April 13, 2021 1:42 AM UTC
Updated on Apr 13, 2021 at 6:37 PM UTC

A study from Guardant Health Inc. (NASDAQ:GH), Amgen Inc. (NASDAQ:AMGN) and academic collaborators showed Guardant’s plasma cell-free DNA (cfDNA)-based Guardant360 CDx test had an 81.5% positive percent agreement and 100% negative percent agreement with a tumor tissue-based test from Qiagen N.V. (NYSE:QGEN; Xetra:QIA) to detect the KRAS G12C mutation. Following treatment with Amgen’s KRAS G12C inhibitor sotorasib (AMG 510), the ORR was 37.1% in patients who were mutation positive by the tissue test, and 36.4% in those positive by the cfDNA test.

Gracell’s allogeneic CD7-targeting CAR T cells
Gracell Biotechnologies Inc. (NASDAQ:GRCL) presented data from an open-label, investigator-initiated study showing five out of six relapsed or refractory T cell lymphoblastic leukemia patients achieved minimal residual disease negative remission (MRD-CR) one month after infusion with GC027, an off-the-shelf CD7-targeting CAR T cell therapy. Three of the five patients were still in MRD-CR in six month follow-up data; one remained MRD-CR 16.8 months...